Height velocity equal to or greater than expected · patients with bone disease in children with chronic kidney disease
It is very uncertain whether calcitriol changes height velocity equal to or greater than expected compared with ergocalciferol (very low certainty).
1 finding from 1 review
Improved bone histology · patients with bone disease in children with chronic kidney disease
It is very uncertain whether calcitriol changes improved bone histology compared with ergocalciferol (very low certainty).
1 finding from 1 review
PTH · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Hypercalcaemia · patients with bone disease in children with chronic kidney disease
It is very uncertain whether calcitriol changes hypercalcaemia compared with ergocalciferol (very low certainty).
1 finding from 1 review
Calcium mg/dL · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Phosphorus mmol/L · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
ALP U/L · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Intervention not reported
Adverse events: hypercalcaemia in trials using the active forms of vitamin D (alfacalcidol and calcitriol) ( · adults
The intervention may leads to higher adverse events: hypercalcaemia in trials using the active forms of… (low certainty).
1 finding from 1 review
Abnormal bone biopsy Bone histology · patients with bone disease in children with chronic kidney disease
Intraperitoneal showed no clear difference in abnormal bone histology Bone biopsy compared with oral calcitriol (low certainty).
1 finding from 1 review
Fall in PTH · patients with bone disease in children with chronic kidney disease
Intermittent oral showed no clear difference in fall in PTH compared with daily oral calcitriol (moderate certainty).
2 findings from 1 review
Kidney function · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Adverse events ‐ Calcium > 11.5 mg/dL · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Adverse events ‐ Phosphorus level > 7.5 mg/dL · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Adynamic bone disease Bone histology · patients with bone disease in children with chronic kidney disease
Intraperitoneal showed no clear difference in adynamic bone disease Bone histology compared with oral calcitriol (low certainty).
1 finding from 1 review
Osteitis fibrosa Bone histology · patients with bone disease in children with chronic kidney disease
Intraperitoneal showed no clear difference in osteitis fibrosa Bone histology compared with oral calcitriol (low certainty).
1 finding from 1 review
PTH · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Adverse events ‐ Calcium > 11 mg/dL · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Adverse events ‐ Phosphate > 7.0 mg/dL · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Peritonitis · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Change in height · patients with bone disease in children with chronic kidney disease
1 finding from 1 review